298 related articles for article (PubMed ID: 16464759)
1. Skin lesions induced by bortezomib.
Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
4. Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Varettoni M; Vassallo C; Borroni G; Mangiacavalli S; Zappasodi P; Rosso R; Lazzarino M; Corso A
Ann Hematol; 2007 Apr; 86(4):301-2. PubMed ID: 17131123
[No Abstract] [Full Text] [Related]
5. Images in clinical Medicine. Bortezomib-induced skin lesions.
Agterof MJ; Biesma DH
N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
[No Abstract] [Full Text] [Related]
6. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
7. Bortezomib-associated rash: a new recognizable and avoidable side-effect.
Villarrubia B; Betlloch I; Mataix J; Lucas A; Botella C
Br J Dermatol; 2007 Apr; 156(4):784-5. PubMed ID: 17286633
[No Abstract] [Full Text] [Related]
8. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Wu KL; Heule F; Lam K; Sonneveld P
J Am Acad Dermatol; 2006 Nov; 55(5):897-900. PubMed ID: 17052502
[TBL] [Abstract][Full Text] [Related]
9. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
10. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Hattori N; Adachi D; Nakashima H; Saito B; Nakamaki T; Tomoyasu S
Leuk Res; 2009 Apr; 33(4):574-7. PubMed ID: 18838167
[No Abstract] [Full Text] [Related]
11. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
12. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
14. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
[TBL] [Abstract][Full Text] [Related]
15. Severe intestinal vasculitis in a patient under treatment with bortezomib.
Mangiacavalli S; Zappasodi P; Castagnola C; Astori C; Varettoni M; Lazzarino M; Corso A
Ann Hematol; 2007 Dec; 86(12):923-4. PubMed ID: 17641890
[No Abstract] [Full Text] [Related]
16. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
19. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Fang B; Song Y; Ma J; Zhao RC
Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
[No Abstract] [Full Text] [Related]
20. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
